Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Long-Term Deferred Tax (2016)

Historic Long-Term Deferred Tax for Pharma (IGC) over the last 8 years, with Q4 2016 value amounting to $19000.0.

  • Pharma's Long-Term Deferred Tax fell 9375.56% to $19000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $19000.0, marking a year-over-year decrease of 9375.56%. This contributed to the annual value of $356684.0 for FY2016, which is 1197.18% up from last year.
  • Pharma's Long-Term Deferred Tax amounted to $19000.0 in Q4 2016, which was down 9375.56% from $356619.0 recorded in Q3 2016.
  • Pharma's 5-year Long-Term Deferred Tax high stood at $356684.0 for Q1 2016, and its period low was -$14076.0 during Q1 2012.
  • Over the past 5 years, Pharma's median Long-Term Deferred Tax value was $318548.0 (recorded in 2015), while the average stood at $287677.3.
  • In the last 5 years, Pharma's Long-Term Deferred Tax skyrocketed by 252579.57% in 2013 and then plummeted by 9375.56% in 2016.
  • Over the past 5 years, Pharma's Long-Term Deferred Tax (Quarter) stood at -$14076.0 in 2012, then soared by 2221.59% to $298635.0 in 2013, then grew by 6.54% to $318159.0 in 2014, then dropped by 4.36% to $304272.0 in 2015, then tumbled by 93.76% to $19000.0 in 2016.
  • Its Long-Term Deferred Tax was $19000.0 in Q4 2016, compared to $356619.0 in Q3 2016 and $356334.0 in Q2 2016.